Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 53,955

Document Document Title
WO/2023/182897A1
The present invention relates to a novel compounds for use in treatment or prevention of cancer, in particular to use of said compounds as an inhibitors of interactions between TRF1-TIN2 or TRF2-TIN2 telomeric proteins.  
WO/2023/182835A1
The present invention relates to a novel organic compound and an organic electroluminescent element using same, and more specifically, to a compound having excellent electron injection and transport capabilities, and an organic electrolu...  
WO/2023/180898A1
This invention relates to a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin -3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine mono succinate salt Form 1. The invention also relates to pharm...  
WO/2023/175632A1
The present invention relates to new solid state forms of (5S,6S,9R)-5-amino-6- (2,3­difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyr idin-9-yl 4-(2-oxo-2,3-dihydro- 1H-imidazo[4,5-b] pyridin-1-yl)-1-piperidinecarboxylate hemisulf...  
WO/2023/178181A1
The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds...  
WO/2023/176609A1
This composition includes an infrared absorbing agent, a curable compound, and a solvent, wherein the infrared absorbing agent includes a compound represented by formula (1). Provided are a film, an optical filter, a solid-state imaging ...  
WO/2023/175491A1
The present disclosure relates to a process for the preparation of pyridine-based halobutyl ionomer with controlled microstructure. The process comprises dissolving a halobutyl rubber in a fluid medium at a temperature in the range of 25...  
WO/2023/173196A1
Disclosed are novel C4-carboxylic acid-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorde...  
WO/2023/174383A1
Provided are a dihydroisoquinoline compound and a medical use thereof. Specifically, the compound has a structure as shown in formula (I), can be used as a regulator for secretion of type-I interferon, especially as a target inhibitor fo...  
WO/2023/174400A1
The present invention provides a salt of a substituted amino six-membered nitric heterocyclic compound, a crystal form thereof, a method for preparing same, and use thereof. Specifically provided is a dihydrochloride salt of a compound r...  
WO/2023/177249A1
The present invention pertains to a novel binary Histone deacetylase (HDAC) inhibitor, and a pharmaceutical composition containing same. More specifically, the compound according to the present invention exhibits more selective and super...  
WO/2023/174351A1
Disclosed in the present invention are a pyrrole amide compound, and a preparation method therefor and the use thereof. The structure of the compound is as represented by formula (I). The compound is a brand-new anti-HBV compound. Furthe...  
WO/2023/177233A1
Provided are a novel compound, a use thereof for inhibiting checkpoint kinase 2 (Chk2), and a use thereof for preventing or treating cancer. Since the compound of the present invention has high Chk2 selectivity, the compound can overcome...  
WO/2023/173219A1
The present document describes a method for improving likelihood of survival in a stage III-IV ovarian cancer patient. The method comprises at least steps of (a) administering daily to a stage III-IV ovarian cancer patient a therapeutica...  
WO/2022/159688A9
Provided herein are compounds (e.g., compounds of Formulae (A-I), (B-I), (C-I)), and pharmaceutically acceptable salts, stereoisomers, tautomers, isotopically labeled derivatives, solvates, hydrates, polymorphs, co-crystals, and prodrugs...  
WO/2023/177250A1
The present invention relates to a novel heterocyclic inhibitor for histone deacetylase (HDAC), a novel therapeutic agent for HDAC-associated diseases, and a pharmaceutical composition comprising same. More specifically, a compound accor...  
WO/2023/175185A1
The present invention relates to a compound of formula (I) or an enantiomer, diastereoisomer, tautomer, pharmaceutically acceptable solvate, pharmaceutically acceptable crystal form or a pharmaceutically acceptable salt thereof. The pres...  
WO/2023/174175A1
A type of KIF18A inhibitor. Specifically provided are a compound represented by general formula (1), a preparation method therefor, and an isomer, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and a ...  
WO/2023/174250A1
This disclosure provides compounds containing 4- (aminomethyl) -6- (1-methyl-1H-pyrazol-4-yl) isoquinolin-1 (2H) -onestructure, the use thereof for selectively inhibiting the activity of PRMT5 in cooperative with MTA in tumors bearing MT...  
WO/2023/174406A1
The present invention relates to a nitrogen-containing heterocyclic derivative EGFR inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by general formula (I)...  
WO/2023/174399A1
The present invention relates to a crystal form of a substituted oxopyridine derivative and to a preparation method therefor. The invention provides a crystal form A of a compound shown in formula (I), as well as a preparation method the...  
WO/2023/177568A1
The application relates to compounds of the general Formula (I) which act as cannabinoid receptor modulators useful for the treatment of complications arising from metabolic, inflammatory and fibrotic disorders.  
WO/2023/174397A1
Described herein are PKMYT1 (Myt1) inhibitors and pharmaceutical compositions comprising said inhibitors. The compounds and compositions are useful for the treatment of a disease or disorder associated with PKMYT1.  
WO/2023/174090A1
The present invention relates to a cocrystal of dabigatran etexilate and a method for preparing same, also relates to a pharmaceutical composition comprising the cocrystal, and further relates to use of the cocrystal in preparing an anti...  
WO/2023/177329A1
The invention relates to the field of pharmaceutics and medicine and concerns the use of 1-(2-(1H-imidazole-4-yl)-ethyl)piperidine-2,6-dione or its pharmaceutically acceptable salt, as well as pharmaceutical compositions containing same,...  
WO/2023/173229A1
Disclosed are salts of C4-carboxylic acid-substituted and C4-carbonothioate-substituted tryptamine derivative compounds represented by chemical formula (I), wherein R4 is a carboxylic acid moiety or a derivative thereof, or a carbonothio...  
WO/2023/168487A1
The present invention is directed to a probe for detecting a transition metal, the probe comprising: a metal chelating portion configured to coordinate with a transition metal; a label portion configured to be detectable; and a linker bo...  
WO/2023/169573A1
Provided is a Polθ inhibitor. Specifically provided are a heterocyclic compound represented by formula I, and a stereoisomer or pharmaceutically acceptable salt thereof, wherein m and n respectively are integers from 0 to 4; and a ring ...  
WO/2023/170025A1
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are amido cyclopropyl derivatives, methods of preparing such compo...  
WO/2023/169461A1
Provided are a thienopyrimidine compound, an intermediate, and a preparation method therefor, a composition thereof and the use thereof, and the present invention specifically relates to a compound as represented by formula (I). Further ...  
WO/2023/169453A1
The present invention relates to a heteroaromatic ring-containing alkynyl compound, and a preparation method therefor and the use thereof. The heteroaromatic ring-containing alkynyl compound is a compound represented by a formula (I), or...  
WO/2023/169535A1
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit the protein (s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life ...  
WO/2023/168686A1
The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with CDK2. This disclosu...  
WO/2023/173083A1
This disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt that inhibits epidermal growth factor receptor (EGER, ERBB1) and/or Human epidermal growth factor receptor 2 (HER2, ERBB2). These compounds of formu...  
WO/2023/169373A1
The present invention relates to a holosymmetric biphenyl derivative, and a preparation method therefor and the use thereof. Particularly, the present invention relates to a holosymmetric biphenyl derivative having the structure of formu...  
WO/2023/170164A1
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with comp...  
WO/2023/170174A1
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with comp...  
WO/2023/168484A1
Compounds of Formula (A) and methods for use as agricultural chemicals, including herbicides: Formula (A)  
WO/2023/170608A1
The present disclosure provides antibody drug conjugates and methods of delivering the conjugates to effector T cells. Also disclosed are novel Cbl-b inhibitors. The compounds and conjugates are useful for treating diseases in subjects i...  
WO/2023/172921A1
The present application provides solid forms and salts of a compound of Formula (I): (I) pharmaceutical compositions thereof, methods of treating a disease or disorder associated with CDK2 using the same, and processes of preparing the c...  
WO/2023/172415A1
Described herein are compounds useful as sweet flavor modifiers. Ingestible compositions that include one or more of these compounds in combination with a natural or artificial sweetener are also described. (I)  
WO/2023/168649A1
The present invention relates to a method for preparing mefunidone hydrochloride. Compared with the prior art, one synthesis step is omitted, and the yield is improved, wherein the yield of step 3 in the present invention is 90.0%, and t...  
WO/2023/169391A1
The present invention relates to a heterocyclic derivative, a preparation method therefor, a pharmaceutical composition containing the derivative, and an application thereof in medicine. Specifically, the present invention relates to a h...  
WO/2023/173016A1
The present disclosure relates to diaryl compounds targeting KRAS, pharmaceutical compositions containing the compounds, and methods of using such compounds to treat disease, such as cancer.  
WO/2023/169481A1
The present invention provides a tetrahydroisoquinoline derivative as a pan-KRAS inhibitor. Specifically, the present invention provides a tetrahydroisoquinoline derivative having a structural formula as shown in general formula (I) and ...  
WO/2023/172112A1
The present specification relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising the compound.  
WO/2023/171665A1
In the production of crops in agriculture, horticulture, etc., due to factors such as damages caused by harmful bugs and the like still being significant and the emergence of harmful bugs resistant to existing drugs, there has been a dem...  
WO/2023/169547A1
A nitrogen-containing heterocyclic compound represented by formula (I-c), or a stereoisomer, a deuterated compound or a pharmaceutically acceptable salt, and a pharmaceutical composition thereof. Also provided is a use of the compound in...  
WO/2023/165874A1
The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein Y1, Y2, Z1, Z2, R1, R2, R5, R6, R9 and n are as defined herein. The invention further relates to herbicidal composit...  
WO/2023/167856A1
Provided herein are methods of treating proliferative diseases or disorders (e.g., a cancer) in a patient in need thereof using a combination therapy of Compound (I) or a pharmaceutically acceptable salt thereof and a PD-1 inhibitor (e.g...  

Matches 651 - 700 out of 53,955